62655-20-3 Usage
General Description
1,3-Dibromo-5-isopropylbenzene is a chemical compound with the molecular formula C9H11Br2. It is a colorless liquid with a sweet, floral odor, and is primarily used as an intermediate in the synthesis of pharmaceuticals, pesticides, and other organic compounds. It is also used as a reagent in organic chemical reactions. The compound is considered hazardous, as it is harmful if swallowed, inhaled, or absorbed through the skin, and may cause irritation to the eyes, skin, and respiratory system. It is important to handle and store 1,3-Dibromo-5-isopropylbenzene with care and follow appropriate safety protocols to minimize the risk of exposure.
Check Digit Verification of cas no
The CAS Registry Mumber 62655-20-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,2,6,5 and 5 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 62655-20:
(7*6)+(6*2)+(5*6)+(4*5)+(3*5)+(2*2)+(1*0)=123
123 % 10 = 3
So 62655-20-3 is a valid CAS Registry Number.
62655-20-3Relevant articles and documents
A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790Mmutant with improved pharmacokinetic properties
Yu, Lei,Huang, Minhao,Xu, Tianfeng,Tong, Linjiang,Yan, Xiao-e,Zhang, Zhang,Xu, Yong,Yun, Caihong,Xie, Hua,Ding, Ke,Lu, Xiaoyun
, p. 1107 - 1117 (2016/12/30)
Structural optimization of pyrido[2,3-d]pyrimidin-7-ones was conducted to yield a series of new selective EGFRT790Minhibitors with improved pharmacokinetic properties. One of the most promising compound 9s potently suppressed EGFRL858R/T790Mkinase and inhibited the proliferation of H1975?cells with IC50values of 2.0?nM and 40?nM, respectively. The compound dose-dependently induced reduction of the phosphorylation of EGFR and downstream activation of ERK in NCI[sbnd]H1975?cells. It also exhibited moderate plasma exposure after oral administration and an oral bioavailability value of 16%. Compound 9s may serve as a promising lead compound for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.
